This proposed S-1 offering prospectus relates to the offering of 47,000,000 shares of common stock of Ludwig Enterprises, Inc. The Offering document is requesting but has not
Sparks, NV – March 20, 2023: Ludwig Enterprises, Inc., OTC: LUDG,(Ludwig – The Genomics LanguageCompany ™) is pleased to announce itintends to file, in the second quarter
Sparks, NV – March 11, 2023: Ludwig Enterprises, Inc. (The Genomics Language Company™)is in discussions with several organizations that should contribute significantly to the company’s revenue growth.
Sparks, NV – March 11, 2023: Ludwig Enterprises, Inc. (The Genomics Language Company™) and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending
Sparks Nevada, March 6, 2023: Ludwig Enterprises, Inc, (OTC: LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee
Sparks NV, February 13, 2023: Ludwig Enterprises (OTC: LUDG), developers of mRNA Inflammatory Index™(Patent Pending) and producers of NuGenea the anti-inflammatory nutraceutical is pleased to announcethat it
February 9, 2023 – Orlando, Florida: Marvin Hausman MD, Chief Medical Officer ofLudwig Enterprises, Inc. and creator of the mRNA Inflammatory Index, lectured University of Central Florida
Sparks Nevada/February 9, 2023: “Chronic inflammation is a silent disorder.” Writes Dr. Marvin S. Hausman MD in his white paper Inflammation: A Unifying Causation of Disease –
This is One More Step in Ludwig’s Planned Path to an NYSE or NASDAQ Listing. SPARKS, NV / ACCESSWIRE / January 12, 2023 / (OTC PINK:LUDG) Ludwig Enterprises Inc.,
Ludwig Enterprises Receives IRB Approval on Bladder Cancer StudymRNA Technology to Assess Patient Response to BCG Immunotherapy Treatment SPARKS, NV / ACCESSWIRE / January 3, 2023 / (OTC